HOLX - Hologic upgraded on M&A strategy and more in today's analyst action

Hologic upgraded on tuck-in M&A strategyEvercore ISI is upgrading share of Hologic ([[HOLX]] -0.4%) to outperform with a $78 price target (~15% upside).The firm says that the women's health and diagnostics player is poised for future tuck-in acquisitions, funded with profits from its COVID-19 diagnostic testing, in areas such as point-of-care diagnostics and breast health.In addition, recent acquisitions have added more than $100M of revenue which Evercore believes can grow at ~20% compound annual growth rate for the foreseeable future.

For further details see:

Hologic upgraded on M&A strategy and more in today's analyst action